By analyzing the crystal structure of the SH2 domain of Grb7, it was found that the effect on Grb7 dimeric status of a synthetic Grb7-binding peptide, which targets the SH2 domain of Grb7, provides a potential strategy for treating Grb7-mediated cancer progression [47]. The gene discussed is GRB7; the disease is cancer.